NASDAQ:PTGX Protagonist Therapeutics (PTGX) Stock Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free PTGX Stock Alerts $27.11 +1.32 (+5.12%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$25.75▼$28.3450-Day Range$24.66▼$32.1552-Week Range$13.72▼$33.34Volume774,650 shsAverage Volume676,839 shsMarket Capitalization$1.59 billionP/E RatioN/ADividend YieldN/APrice Target$38.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Protagonist Therapeutics alerts: Email Address Protagonist Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside40.2% Upside$38.00 Price TargetShort InterestBearish6.00% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.82Based on 8 Articles This WeekInsider TradingSelling Shares$2.55 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom $1.18 to ($0.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.61 out of 5 starsMedical Sector745th out of 905 stocksPharmaceutical Preparations Industry351st out of 422 stocks 3.5 Analyst's Opinion Consensus RatingProtagonist Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageProtagonist Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Protagonist Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.00% of the outstanding shares of Protagonist Therapeutics have been sold short.Short Interest Ratio / Days to CoverProtagonist Therapeutics has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Protagonist Therapeutics has recently increased by 2.33%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldProtagonist Therapeutics does not currently pay a dividend.Dividend GrowthProtagonist Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PTGX. Previous Next 2.7 News and Social Media Coverage News SentimentProtagonist Therapeutics has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Protagonist Therapeutics this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 2 people have added Protagonist Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Protagonist Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,553,328.00 in company stock.Percentage Held by InsidersOnly 5.00% of the stock of Protagonist Therapeutics is held by insiders.Percentage Held by Institutions98.63% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Protagonist Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Protagonist Therapeutics are expected to decrease in the coming year, from $1.18 to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protagonist Therapeutics is -18.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Protagonist Therapeutics is -18.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProtagonist Therapeutics has a P/B Ratio of 4.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Protagonist Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Protagonist Therapeutics Stock (NASDAQ:PTGX)Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Read More PTGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PTGX Stock News HeadlinesApril 20, 2024 | insidertrades.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Asif Ali Sells 1,234 SharesMay 8, 2024 | markets.businessinsider.comProtagonist Therapeutics: Strong Buy Rating on Robust Financials and Promising PipelineMay 9, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. May 8, 2024 | investorplace.comPTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | chron.comProtagonist Therapeutics: Q1 Earnings SnapshotMay 7, 2024 | finance.yahoo.comProtagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic CollaborationsApril 29, 2024 | finance.yahoo.comWe Might See A Profit From Protagonist Therapeutics, Inc. (NASDAQ:PTGX) SoonApril 26, 2024 | finance.yahoo.comProtagonist Therapeutics, Inc. (PTGX)May 9, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 3, 2024 | finance.yahoo.comProtagonist Therapeutics Inc CEO Sells 25,000 SharesApril 1, 2024 | finance.yahoo.comShareholders have faith in loss-making Protagonist Therapeutics (NASDAQ:PTGX) as stock climbs 3.7% in past week, taking five-year gain to 135%March 27, 2024 | markets.businessinsider.comProtagonist Therapeutics Earns ‘Buy’ Rating on Strong Clinical Progress and Strategic PartnershipsMarch 18, 2024 | finanznachrichten.deProtagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with TakedaMarch 15, 2024 | finance.yahoo.comPTGX Apr 2024 15.000 callMarch 15, 2024 | finance.yahoo.comPTGX Apr 2024 30.000 putMarch 12, 2024 | bizjournals.comThe People's Market owner snaps up former Protagonist space in heart of NoDa for barMarch 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Protagonist Therapeutics on Strong Phase 2b Results and Strategic Phase 3 Dosing of JNJ-2113March 11, 2024 | markets.businessinsider.comStrong Buy Rating for Protagonist Therapeutics on JNJ-2113’s Promising Psoriasis Treatment Efficacy and Financial OutlookMarch 3, 2024 | finance.yahoo.comThis Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This YearMarch 2, 2024 | finance.yahoo.comEarnings Update: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Just Reported And Analysts Are Boosting Their EstimatesMarch 1, 2024 | finance.yahoo.comProtagonist Therapeutics Full Year 2023 Earnings: Beats ExpectationsFebruary 29, 2024 | finance.yahoo.comWe're Not Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash BurnFebruary 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Protagonist Therapeutics on Strong Pipeline and Strategic PartnershipsFebruary 28, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Gritstone Oncology (GRTS), Protagonist Therapeutics (PTGX)February 25, 2024 | seekingalpha.comProtagonist Therapeutics: Why I Remain On Sidelines Despite Obvious PromiseFebruary 21, 2024 | finance.yahoo.comNew England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia VeraFebruary 20, 2024 | finance.yahoo.comProtagonist Therapeutics Reports Granting of Inducement AwardsSee More Headlines Receive PTGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today5/08/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PTGX CUSIPN/A CIK1377121 Webwww.protagonist-inc.com Phone(510) 474-0170FaxN/AEmployees112Year FoundedN/APrice Target and Rating Average Stock Price Target$38.00 High Stock Price Target$45.00 Low Stock Price Target$32.00 Potential Upside/Downside+32.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.49) Trailing P/E RatioN/A Forward P/E Ratio22.97 P/E GrowthN/ANet Income$-78,960,000.00 Net MarginsN/A Pretax Margin-131.59% Return on Equity-27.49% Return on Assets-25.30% Debt Debt-to-Equity RatioN/A Current Ratio16.71 Quick Ratio16.71 Sales & Book Value Annual Sales$60 million Price / Sales26.50 Cash FlowN/A Price / Cash FlowN/A Book Value$5.84 per share Price / Book4.64Miscellaneous Outstanding Shares58,640,000Free Float55,711,000Market Cap$1.59 billion OptionableOptionable Beta2.09 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Dinesh V. Patel Ph.D. (Age 67)CEO, President, Secretary & Director Comp: $883.46kDr. Suneel K. Gupta Ph.D. (Age 65)Chief Development Officer Comp: $640.89kDr. Mark Smythe Ph.D. (Age 59)Founder & VP Technology Mr. Asif Ali (Age 50)Executive VP & Chief Financial Officer Mr. Mohammad Masjedizadeh Ph.D.Executive VP & Chief Technical OfficerMr. Matthew M. Gosling (Age 53)Executive VP & General Counsel Ms. Carena SpiveyHead of HR & Senior VP of Human ResourcesDr. Ashok Bhandari Ph.D. (Age 60)Executive VP & Chief Drug Discovery and Preclinical Development Officer Mr. Carter J. King (Age 53)Executive Vice President of Business Development Ms. Abha BommireddiExecutive Vice President of Portfolio & Program ManagementMore ExecutivesKey CompetitorsMorphicNASDAQ:MORFAkero TherapeuticsNASDAQ:AKROXencorNASDAQ:XNCRDay One BiopharmaceuticalsNASDAQ:DAWNDynavax TechnologiesNASDAQ:DVAXView All CompetitorsInsiders & InstitutionsState Board of Administration of Florida Retirement SystemSold 4,980 shares on 5/9/2024Ownership: 0.019%ProShare Advisors LLCBought 1,206 shares on 5/8/2024Ownership: 0.024%Inspire Investing LLCSold 4,442 shares on 5/8/2024Ownership: 0.021%Russell Investments Group Ltd.Bought 1,216 shares on 5/8/2024Ownership: 0.002%Sei Investments Co.Bought 4,529 shares on 5/7/2024Ownership: 0.071%View All Insider TransactionsView All Institutional Transactions PTGX Stock Analysis - Frequently Asked Questions Should I buy or sell Protagonist Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTGX shares. View PTGX analyst ratings or view top-rated stocks. What is Protagonist Therapeutics' stock price target for 2024? 4 Wall Street research analysts have issued 1-year price objectives for Protagonist Therapeutics' stock. Their PTGX share price targets range from $32.00 to $45.00. On average, they expect the company's stock price to reach $38.00 in the next twelve months. This suggests a possible upside of 40.2% from the stock's current price. View analysts price targets for PTGX or view top-rated stocks among Wall Street analysts. How have PTGX shares performed in 2024? Protagonist Therapeutics' stock was trading at $22.93 at the beginning of the year. Since then, PTGX shares have increased by 18.2% and is now trading at $27.11. View the best growth stocks for 2024 here. When is Protagonist Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our PTGX earnings forecast. How were Protagonist Therapeutics' earnings last quarter? Protagonist Therapeutics, Inc. (NASDAQ:PTGX) released its quarterly earnings data on Tuesday, February, 27th. The company reported $0.44 EPS for the quarter, topping analysts' consensus estimates of $0.05 by $0.39. The company earned $60 million during the quarter, compared to analyst estimates of $60 million. What ETFs hold Protagonist Therapeutics' stock? ETFs with the largest weight of Protagonist Therapeutics (NASDAQ:PTGX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of Protagonist Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE). When did Protagonist Therapeutics IPO? Protagonist Therapeutics (PTGX) raised $70 million in an IPO on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO. Who are Protagonist Therapeutics' major shareholders? Protagonist Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Privium Fund Management B.V. (0.20%), GSA Capital Partners LLP (0.09%), BNP Paribas Financial Markets (0.08%), Sei Investments Co. (0.07%), Hennion & Walsh Asset Management Inc. (0.06%) and Los Angeles Capital Management LLC (0.05%). Insiders that own company stock include Asif Ali, David Y Liu, Dinesh V Ph D Patel, Suneel Gupta and William D Waddill. View institutional ownership trends. How do I buy shares of Protagonist Therapeutics? Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PTGX) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithDems have chosen Biden replacement?Paradigm PressGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchObama’s Forever Term [exposed]Porter & CompanyPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
